Compare THQ & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THQ | HELP |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.0M | 889.9M |
| IPO Year | N/A | 2020 |
| Metric | THQ | HELP |
|---|---|---|
| Price | $19.10 | $12.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 112.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 07-01-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.28 | $3.76 |
| 52 Week High | $20.39 | $14.35 |
| Indicator | THQ | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 52.58 |
| Support Level | $18.88 | $11.26 |
| Resistance Level | $19.41 | $14.35 |
| Average True Range (ATR) | 0.27 | 1.04 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 24.21 | 33.76 |
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.